Page 18 - Read Online

Di Raimo et al. J Cancer Metastasis Treat 2018;4:54 I http://dx.doi.org/10.20517/2394-4722.2018.50 Page 9 of 14

Copyright
© The Author(s) 2018.

REFERENCES
1. Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. Global, regional, and national cancer incidence, mortality,
years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for
the global burden of disease study. JAMA Oncol 2018; doi: 10.1001/jamaoncol.2018.2706.
2. Al-Foheidi M, Al-Mansour MM, Ibrahim EM. Breast cancer screening: review of benefits and harms, and recommendations for developing
and low-income countries. Med Oncol 2013;30:471.
3. Gyawali B, Shimokata T, Honda K, Tsukuura H, Ando Y. Should low-income countries invest in breast cancer screening? Cancer Causes
Control 2016;27:1341-5.
4. Lee M, Mariapun S, Rajaram N, Teo SH, Yip CH. Performance of a subsidised mammographic screening programme in Malaysia, a middle-
income Asian country. BMC Public Health 2017;17:127.
5. Rivera-Franco MM, Leon-Rodriguez E. Delays in breast cancer detection and treatment in developing countries. Breast Cancer (Auckl)
2018;12:1178223417752677.
6. Dai X, Li T, Bai Z, Yang Y, Liu X, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res
2015;5:2929-43.
7. Lammert J, Grill S, Kiechle M. Modifiable lifestyle factors: opportunities for (hereditary) breast cancer prevention - a narrative review.
Breast Care (Basel) 2018;13:109-14.
8. Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, et al. Association between common risk factors and molecular subtypes in breast
cancer patients. Breast 2013;22:344-50.
9. Li J, Chen Z, Su K, Zeng J. Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J Clin Exp Pathol
2015;8:8500-5.
10. Hammond ME. ASCO-CAP guidelines for breast predictive factor testing: an update. Appl Immunohistochem Mol Morphol
2011;19:499-500.
11. Advani PP, Crozier JA, Perez EA. HER2 testing and its predictive utility in anti-HER2 breast cancer therapy. Biomark Med 2015;9:35-49.
12. Bandyopadhyay S, Bluth MH, Ali-Fehmi R. Breast carcinoma: updates in molecular profiling 2018. Clin Lab Med 2018;38:401-20.
13. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
14. Gusterson B, Eaves CJ. Basal-like breast cancers: from pathology to biology and back again. Stem Cell Reports 2018;10:1676-86.
15. Iancu G, Vasile D, Iancu RC, DaviŢoiu DV. “Triple positive” breast cancer - a novel category? Rom J Morphol Embryol 2017;58:21-6.
16. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J
Med 2006;355:560-9.
17. Li Z, Qiu Y, Lu W, Jiang Y, Wang J. Immunotherapeutic interventions of triple negative breast cancer. J Transl Med 2018;16:147.
18. Jitariu AA, Cîmpean AM, Ribatti D, Raica M. Triple negative breast cancer: the kiss of death. Oncotarget 2017;8:46652-62.
19. Yousefi M, Nosrati R, Salmaninejad A, Dehghani S, Shahryari A, et al. Organ-specific metastasis of breast cancer: molecular and cellular
mechanisms underlying lung metastasis. Cell Oncol (Dordr) 2018;41:123-40.
20. Wu SG, Li H, Tang LY, Sun JY, Zhang WW, et al. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: a
SEER database analysis. Tumour Biol 2017;39:1010428317705082.
21. Appierto V, Di Cosimo S, Reduzzi C, Pala V, Cappelletti V, et al. How to study and overcome tumor heterogeneity with circulating
biomarkers: the breast cancer case. Semin Cancer Biol 2017;44:106-16.
22. Masuda T, Hayashi N, Iguchi T, Ito S, Eguchi H, et al. Clinical and biological significance of circulating tumor cells in cancer. Mol Oncol
2016;10:408-17.
23. Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab Sci
2014;51:160-71.
24. Hiller JG, Perry NJ, Poulogiannis G, Riedel B, Sloan EK. Perioperative events influence cancer recurrence risk after surgery. Nat Rev Clin
Oncol 2018;15:205-18.
25. Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, et al. Clinical validity of circulating tumour cells in patients with metastatic
breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014;15:406-14.
26. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant
chemotherapy: a meta-analysis. J Natl Cancer Inst 2018;110:560-7.
27. Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, et al. Circulating tumor cells: clinical validity and utility. Int J Clin Oncol
2017;22:421-30.
28. Tungsukruthai S, Petpiroon N, Chanvorachote P. Molecular mechanisms of breast cancer metastasis and potential anti-metastatic
compounds. Anticancer Res 2018;38:2607-18.
29. Micalizzi DS, Maheswaran S, Haber DA. A conduit to metastasis: circulating tumor cell biology. Genes Dev 2017;31:1827-40.
30. Scully OJ, Bay BH, Yip G, Yu Y. Breast cancer metastasis. Cancer Genomics Proteomics 2012;9:311-20.
31. Dasgupta A, Lim AR, Ghajar CM. Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol Oncol
2017;11:40-61.
32. Krawczyk N, Meier-Stiegen F, Banys M, Neubauer H, Ruckhaeberle E, et al. Expression of stem cell and epithelial-mesenchymal transition
markers in circulating tumor cells of breast cancer patients. Biomed Res Int 2014;2014:415721.